Background
==========

Our recent work on the mechanism of action of 2'-deoxyriboguanylurea (GuaUre-dR) \[[@B1]\], the primary breakdown product of 5-aza-2'-deoxycytidine (5azaC-dR) \[[@B2]\], coupled with work from multiple laboratories, as well as our own, on DNA methyltransferases (DNMTs) \[[@B3]-[@B8]\], the substrate specificity, mechanism of action and biological effects of helicases, such as the ERCC2, ATRX, HELLS and RecQ family of helicases \[[@B9]-[@B15]\], and the ten-eleven translocation (TET) dioxygenases \[[@B16]-[@B19]\], suggest that the mechanism responsible for most of the hypermethylation observed during carcinogenesis involves the breakdown of an epigenetic repair cycle that maintains the unmethylated state at and near the common fragile sites.

The classic examples of epigenetic downregulation in human cells and tissues are genes that are often silenced and hypermethylated during tumorigenesis. As demonstrated in Table [1](#T1){ref-type="table"}, the vast majority of these genes reside at cytogenetic locations that define well-known fragile sites. This remarkable cytogenetic correspondence strongly suggests that hypermethylation, epigenetic downregulation and chromosomal fragility share common mechanistic features. The best-known feature of fragile sites is the presence of a sequence motif that is prone to the spontaneous formation of a non-B DNA structure. In addition to FRAXA \[[@B14]\], many other fragile sites have been shown to harbor sequences, such as the CCG triplet repeat, which form hairpins, slippage intermediates (Figure [1](#F1){ref-type="fig"}A) and quadruplex structures. Non-B intermediates are known to be exceptional substrates for *de novo* methylation by DNA methyltransferase 1 (DNMT1) \[[@B6],[@B7],[@B20]\] either at its three-nucleotide recognition motif (Figure [1](#F1){ref-type="fig"}) within the repeat if it contains CG sites or at the same motif at CG sites flanking the non-B sequence if it does not. Consequently, even fragile sites that contain AT-rich sequences with high torsional flexibility and the potential for non-B DNA structure formation are subject to methylation in regions flanking the repeat. Other fragile sites that lack CG dimers, such as the Huntington's disease CAG repeat, which can also form hairpins and slippage intermediates \[[@B7],[@B21]\], appear to induce methylation at the flanking and other regions where CG dimers occur \[[@B7],[@B22]\]; for a review, see Lukusa and Fryns \[[@B23]\].

###### 

Hypermethylation at known fragile sites

  **Gene**     **Gene location**   **Fragile site**   **Fragile site type**   **Fragile site location**   **Methylation reference**
  ------------ ------------------- ------------------ ----------------------- --------------------------- ---------------------------
  *RUNX3*      1p36                FRA1A              Aph, C                  1p36                        \[[@B24]\]
  \-           \-                  FRA1B              Aph, C                  1p32                        \-
  *ARHI*       1p31                FRA1C              Aph, C                  1p31.2                      \[[@B25]\]
  *PARG1*      1p22.1              FRA1D              Aph, C                  1p22                        \[[@B26]\]
  \-           \-                  FRA1E              Aph, C                  1p21.2                      \-
  *S100A6*     1q21                FRA1F              Aph, C                  1q21                        \[[@B27]\]
  *-*          \-                  FRA1G              Aph, C                  1q25.1                      \-
  *PTGS2*      1q25.2-25.3         FRA1G              Aph, C                  1q25.1                      \[[@B28],[@B29]\]
  *DISC1*      1q42.1              FRA1H              5azaC-R, C              1q42                        \[[@B30]\]
  \-           \-                  FRA1I              Aph, C                  1q44                        \-
  \-           \-                  FRA1J              5azaC-R, C              1q12                        \-
  *GLUL*       1q31                FRA1K              Aph, C                  1q31                        \[[@B31]\]
  *CLCA2*      1p31                FRA1L              Aph, C                  1p31                        \[[@B32]\]
  *MIR137*     1p21.3              FRA1M              Fol, R                  1p21.3                      \[[@B33]\]
  \-           \-                  FRA2A              Fol, R                  2q11.2                      \-
  *BCL2L11*    2q13                FRA2B              Fol, R                  2q13                        \[[@B34]\]
  \-           \-                  FRA2C              Aph, C                  2p24.2                      \-
  *MSH6*       2p16                FRA2D              Aph, C                  2p16.2                      \[[@B35]\]
  *DOK1*       2p13                FRA2E              Aph, C                  2p13                        \[[@B36]\]
  *RASSF1*     3p21.3              \-                 \-                      \-                          \[[@B37]\]
  *MLH1*       3p21.3              \-                 \-                      \-                          \[[@B38]\]
  *VHL*        3p25.3              \-                 \-                      \-                          \[[@B39]\]
  *LRP1B*      2q21.2              FRA2F              Aph, C                  2q21.3                      \[[@B40]\]
  *HOXD1*      2q31.1              FRA2G              Aph, C                  2q31                        \[[@B41]\]
  \-           \-                  FRA2H              Aph, C                  2q32.1                      \-
  *FLIP*       2q33-q34            FRA2I              Aph, C                  2q33                        \[[@B42]\]
  *KIF1A*      2q37.3              FRA2J              Aph, C                  2q37.3                      \[[@B43]\]
  *ZEB2*       2q22.3              FRA2K              Fol, R                  2q22.3                      \[[@B44]\]
  *RARβ*       3p24.2              FRA3A              Aph, C                  3p24.2                      \[[@B45]\]
  *FHIT*       3p14.2              FRA3B              Aph, C                  3p14.2                      \[[@B46]\]
  \-           \-                  FRA3C              Aph, C                  3q27                        \-
  *RARRES1*    3q25.32             FRA3D              Aph, C                  3q25                        \[[@B47]\]
  *PTX3*       3q25                FRA3D              Aph, C                  3q25                        \[[@B48]\]
  \-           \-                  FRA4A              Aph, C                  4p16.1                      \-
  *PDGFRA*     4q12                FRA4B              BrdU, C                 4q12                        \[[@B49]\]
  *SFRP2*      4q31.3              FRA4C              Aph, C                  4q31.1                      \[[@B50]\]
  *SLIT2*      4p15.2              FRA4D              Aph, C                  4p15                        \[[@B51]\]
  \-           \-                  FRA5A              BrdU, C                 5p13                        \-
  \-           \-                  FRA5B              BrdU, C                 5q15                        \-
  *NR3C1*      5q31.3              FRA5C              Aph, C                  5q31.1                      \[[@B52]\]
  *GPR150*     5q15                FRA5D              Aph, C                  5q15                        \[[@B53]\]
  \-           \-                  FRA5E              Aph, C                  5p14                        \-
  *APC*        5q21-22             FRA5F              Aph, C                  5q21                        \[[@B54]\]
  \-           \-                  FRA5G              Fol, R                  5q35                        \-
  *SCGB3A1*    5q35.3              FRA5G              Fol, R                  5q35                        \[[@B55],[@B56]\]
  \-           \-                  FRA6A              Fol, R                  6p23                        \-
  \-           \-                  FRA6B              Aph, C                  6p25.1                      \-
  \-           \-                  FRA6C              Aph, C                  6p22.2                      \-
  \-           \-                  FRA6C              Aph, C                  6p22.2                      \-
  \-           \-                  FRA6D              BrdU, C                 6q13                        \-
  *ESR1*       6q25.1              \-                 \-                      \-                          \[[@B57]\]
  \-                               FRA6E              Aph, C                  6q26                        \-
  *HACE1*      6q21                FRA6F              Aph, C                  6q21                        \[[@B58]\]
  \-           \-                  FRA6G              Aph, C                  6q15                        \-
  \-           \-                  FRA7A              Fol, R                  7p11.2                      \-
  *TWIST1*     7p21.2              \-                 \-                      \-                          \[[@B56]\]
  \-           \-                  FRA7B              Aph, C                  7p22                         
  \-           \-                  FRA7C              Aph, C                  7p14.2                      \-
  *IGFBP3*     7p13-p12            FRA7D              Aph, C                  7p13                        \[[@B59]\]
  *HIC1*       17p13.3             FRA7D              Aph, C                  7p13                        \[[@B60]\]
  *ABCB1*      7q21.12             FRA7E              Aph, C                  7q21.2                      \[[@B61]\]
  *TFPI2*      7q22                FRA7F              Aph, C                  7q22                        \[[@B62]\]
  *TES*        7q31.2              FRA7G              Aph, C                  7q31.2                      \[[@B63]\]
  *CFTR*       7q31.2              FRA7G              Aph, C                  7q31.2                      \[[@B64]\]
  \-           \-                  FRA7H              Aph, C                  7q32.3                      \-
  *EN2*        7q36                FRA7I              Aph, C                  7q36                        \[[@B65]\]
  *HSPB1*      7q11.23             FRA7J              Aph, C                  7q11                        \[[@B66]\]
  \-           \-                  FRA8A              Fol, R                  8q22.3                      \-
  \-           \-                  FRA8B              Aph, C                  8q22.1                      \-
  *MYC*        8q24.21             FRA8C,             Aph, C                  8q24.1                      \[[@B67]\]
  \-           \-                  FRA8D              Aph, C                  8q24.3                      \-
  *MYC*        8q24.21             FRA8E              Dmy, R                  8q24.1                      \[[@B67]\]
  *CDKN2A*     9p21                FRA9A,             Fol, R                  9p21                        \[[@B68]\]
  *CDKN2B*     9p21                FRA9A,             Fol, R                  9p21                        \[[@B69]\]
  *BRINP1*     9q32-q33            FRA9B,             Fol, R                  9q32                        \[[@B70]\]
  *CDKN2A*     9p21                FRA9C,             BrdU, R                 9p21                        \[[@B68]\]
  *CDKN2B*     9p21                FRA9C,             BrdU, R                 9p21                        \[[@B69]\]
  *DAPK1*      9q21.33             FRA9D              Aph, C                  9q22.1                      \[[@B71]\]
                                   FRA9B,             Aph, C                  9q32                         
  *BARX1*      9q12                FRA9F              5azaC-R, C              9q12                        \[[@B72]\]
  *FRA10AC1*   10q23.33            FRA10A             Fol, R                  10q23.3                     \[[@B73]\]
  *PTEN*       10q23.3             FRA10A             Fol, R                  10q23.3                     \[[@B74]\]
  \-                               FRA10B             BrdU, R                 10q25.2                      
                                   FRA10C             BrdU, R                 10q21                        
  *EGR2*       10q21.1             FRA10D             Aph, C                  10q21.1                     \[[@B75]\]
  *TYSND1*     10q22.1             FRA10D             Aph, C                  10q22.1                     \[[@B76]\]
  \-           \-                  FRA10E             Aph, C                  10q25.2                      
  *MGMT*       10q26               FRA10F             Aph, C                  10q26.1                     \[[@B77]\]
  *RET*        10q11.2             FRA10G             Aph, C                  10q11.2                     \[[@B78]\]
  *MRPL48*     11q13.4             FRA11A             Fol, R                  11q13.3                     \[[@B79]\]
  *AMICA1*     11q23.3             FRA11B             Fol, R                  11q23.3                     \[[@B80]\]
  *CALCB*      11p15.2-            FRA11C             Aph, C                  11p15.1                     \[[@B81]\]
  *HRAS*       11p15.5             FRA11C,            Aph, C                  11p15.1                     \[[@B81]\]
  *MYOD1*      11p15.4             FRA11C,            Aph, C                  11p15.1                     \[[@B64]\]
  \-           \-                  FRA11D             Aph, C                  11p14.2                      
  *WT1*        11p13               FRA11E             Aph, C                  11p13                       \[[@B82]\]
  *CD44*       11p13               FRA11E             Aph, C                  11p13                       \[[@B83]\]
  \-           \-                  FRA11F             Aph, C                  11p14.2                      
  *PGR*        11q22-q23           FRA11G             Aph, C                  11q23.3                     \[[@B84]\]
  *GSTP1*      11q13               FRA11H             Aph, C                  11q13                       \[[@B85]\]
  *CCND2*      12p13               \-                 \-                      \-                          \[[@B56]\]
  *CALCB*      11p15.2-15.1        FRA11I             Aph, C                  11p15.1                     \[[@B81]\]
  *HRAS*       11p15.5             FRA11I,            Aph, C                  11p15.1                     \[[@B81]\]
  *MYOD1*      11p15.4             FRA11I,            Aph, C                  11p15.1                     \[[@B64]\]
  \-           \-                  FRA12A             Fol, R                  12q13.1                      
  *SLC6A15*    12q21.3             FRA12B             Aph, C                  12q21.3                     \[[@B62]\]
  *CHFR*       12q24.33            FRA12C             BrdU, R                 12q24.2                     \[[@B86]\]
  \-           \-                  FRA12D             Fol, R                  12q24.13                     
  *SELPLG*     12q24               FRA12E             Aph, C                  12q24                       \[[@B87]\]
  *BRCA2*      13q12.3             FRA13A             Aph, C                  13q13.2                     \[[@B35]\]
  *RB1*        13q14.2             \-                 \-                      \-                          \[[@B88]\]
  *PCDH20*     13q21.2             FRA13B             BrdU, C                 13q21                       \[[@B89]\]
  *PCDH20*     13q21.2             FRA13C             Aph, C                  13q21.2                     \[[@B89]\]
  *ZIC2*       13q32               FRA13D             Aph, C                  13q32                       \[[@B90]\]
  \-           \-                  FRA15A             Aph, C                  15q22                        
  *ABCC6*      16p13.1             FRA16A             Fol, R                  16p13.11                    \[[@B64]\]
  *CDH1*       16q22.1             FRA16B,            Dmy, R                  16q22.1                     \[[@B91]\]
  *CDH1*       16q22.1             FRA16C             Aph, C                  16q22.1                     \[[@B91]\]
  *CDH13*      16q23.3             FRA16D             Aph, C                  16q23.2                     \[[@B92]\]
  *WWOX*       16q23.3-q24.1       FRA16D             Aph, C                  16q23.2                     \[[@B93]\]
  *HIC1*       17p13.3             \-                 \-                      \-                          \[[@B60]\]
  *-*          \-                  FRA17A             Dmy, R                  17p12                        
  *BRCA1*      17q21.31            \-                 \-                      \-                          \[[@B94]\]
  *SOX9*       17q23               FRA17B             Aph, C                  17q23.1                     \[[@B95]\]
  *CDH2*       18q12.1             FRA18A             Aph, C                  18q12.2                     \[[@B72]\]
  *SERPINB5*   18q21.33            FRA18B             Aph, C                  18q21.3                     \[[@B96]\]
  *BCL2*       18q21.3             FRA18B             Aph, C                  18q21.3                     \[[@B64]\]
  \-           \-                  FRA18C             Aph, C                  18q22.2                      
  \-           \-                  FRA19A             5azaC-R, C              19q13                        
  \-           \-                  FRA19B             Fol, R                  19p13                        
  \-           \-                  FRA20A             Fol, R                  20p11.23                     
  \-           \-                  FRA20B             Aph, C                  20p12.2                      
  \-           \-                  FRA20B             Aph, C                  20p12.2                      
  *FBLN1*      22q13               FRA22A             Fol, R                  22q13                       \[[@B97]\]
  \-           22q12.1             FRA22B             Aph, C                  22q12.2                      
  *AR*         Xq12                \-                 \-                      \-                          \[[@B98]\]
  *FMR1*       Xq27.3              FRAXA              Fol, R                  Xq27.3                      \[[@B14]\]
  *VCX*        Xp22                FRAXB              Aph, C                  Xp22.31                     \[[@B99]\]
  *VCX*        Xp22                FRAXC              Aph, C                  Xq22.1                      \[[@B99]\]
  *FMR1*       Xq27.3              FRAXD              Aph, C                  Xq27.2                      \[[@B100]\]
  *FMR2*       Xq28                FRAXE,             Fol, R                  Xq28                        \[[@B101]\]
  *FMR2*       Xq28                FRAXF              Fol, R                  Xq28                        \[[@B101]\]

Definitions for standard gene abbreviations are available at the HUGO Gene Nomenclature Committee (HGNC) website \[[@B102]\]. Aph, aphidicolin; 5azaC-R, 5-azacytidine ; BrdU, bromodeoxyuridine; C, common; Dmy, distamycin; Fol, folate; R, rare.

![**Key systems maintaining the active and unmethylated state of DNA at sequences with the innate potential for non-B DNA structure formation.** In this enzymologically-based model, non-B DNA structure forms spontaneously or in response to replication stress or carcinogen-linked damage, inducing DNA methylation *de novo*\[[@B3],[@B4],[@B103],[@B104]\]*.* The three-nucleotide recognition motif \[[@B4]\] of DNMT1 (C:G-C) is highlighted in the schematic of the non-B structure in the upper right of the figure. Helicase resolution at non-B structures produces hemimethylated DNA. Hypermethylation is prevented by the action of TET dioxygenase on its preferred hemimethylated substrate \[[@B17]\]. When stress overwhelms the capacity of TET dioxygenase to hydroxymethylate hemimethylated DNA in the affected region, hypermethylation will result. In this model, helicase lesions, DNMT lesions or TET dioxygenase lesions are expected to generate chromosome instability and the selective induction of fragile sites. Methylated unusual DNA structures that are not resolved by helicase action may be removed by excision repair-linked pathways where the unmethylated state is restored by DNA synthesis. **(A)** Molecular model of the hypermethylated C-rich strand hairpin formed at fragile site FRAXA. The model was constructed in Biograf 3.1 (Molecular Simulations Inc, San Diego, CA, USA) and rendered with the UCSF Chimera package (Resource for Biocomputing, Visualization, and Informatics, University of California, San Francisco, CA, USA). It is based on NMR data presented by Chen *et al.*\[[@B20]\]. **(B)** Activity of human DNA methyltransferase 1 (hDNMT1) on hemimethylated DNA and hemihydroxymethylated DNA. hDNMT1 was purified from nuclear extracts \[[@B105]\] prepared from cultured HeLa S3 cells. Purification and enzyme activity measurements were carried out as previously described \[[@B106],[@B107]\]. The purified enzyme had a specific activity of 20.96 fmole^3^HCH~3~/min/mg. Duplex ODN substrates were synthesized and annealed as previously described \[[@B107]\]. The results confirm the findings of Hashimoto *et al*. \[[@B17]\] with cloned DNMT1.](1868-7083-5-17-1){#F1}

Presentation of the hypothesis
==============================

The key components of the hypothesis, presented in Figure [1](#F1){ref-type="fig"}, are: 1) carcinogenesis-linked hypermethylation that occurs primarily at or near fragile sites as a result of the tendency of DNA sequences at these sites to form non-B structures; 2) methylation is applied *de novo* to these structures and their neighboring sequences not only by DNMT3A/3B but also by DNMT1; 3) during normal replication methylated non-B DNA structures are returned to the B form by ERCC2, ATRX, HELLS and RecQ helicases; 4) sequences that cannot be resolved by helicase action are removed by excision; 5) hydroxymethylation applied to the nascent methyl groups by the action of TET dioxygenases prevents sequences that are resolved by helicase action from undergoing maintenance methylation by DNMT1, regenerating the unmethylated state at these sites in normal cells (in this regard, it is important to recognize that resolution of these structures will result in hemimethylated DNA, and that hemimethylated DNA is the preferred substrate of TET1 dioxygenase \[[@B17]\]); and 6) in addition to DNA damage, carcinogenesis-linked dysfunction among the helicases results in hypermethylation at and near fragile sites, and hypomethylation elsewhere.

Testing the hypothesis
======================

While the existing evidence for the proposed cycle is compelling, currently available experimental approaches permit several additional tests of the hypothesis. For example, transient knockdown by transfection-mediated expression of an ERCC2, ATRX, HELLS or RecQ helicase is predicted to result in a transient hypermethylation, coupled with an increase in local hydroxymethylation content at affected fragile sites. Stable knockdown is expected to result in both hypermethylation at affected fragile sites and global hypomethylation. In particular, the knockdown of the WRN helicase (REQL2) is predicted to result in hypermethylation of the *FHIT* gene at FRA3B \[[@B108]\], coupled with enhanced bisulfite sensitivity \[[@B109]\] of native DNA associated with the increased presence of non-B DNA structure at this site \[[@B109],[@B110]\]. Existing studies on the effect of WRN mutations on methylation, for example, do not address early events at fragile sites, since they use cell lines that have been carried in culture or were isolated from adults bearing the WRN mutation \[[@B111],[@B112]\]. Chromatin immunoprecipitation with antibodies to DNMT1 is expected to yield DNA that is enriched for fragile site sequences after helicase knockdown. Determining the levels of DNMT1 by immunoblotting after helicase knockdown would determine whether or not the removal of stalled DNMT1 involves proteolysis \[[@B113]\]. WRN knockdown coupled with DNMT1 knockdown is expected to produce enhanced bisulfite sensitivity \[[@B109],[@B110]\] in the absence of hypermethylation, while enhanced bisulfite sensitivity after knockdown of DNMT1 alone would provide evidence for an obligatory role of methylation in non-B structure resolution.

Finally, as a test of the downstream portion of the cycle, overexpression of TET dioxygenases is expected to reduce *de novo* methylation at fragile sites caused by helicase knockdown, and knockdown of the dioxygenases should enhance *de novo* methylation at these same sites.

Implications of the hypothesis
==============================

The hypothesis is consistent with other suggestions for the genesis of hypermethylation \[[@B114],[@B115]\]. Disruptions in the histone code might be expected to elicit fragile site formation, since exposure to carcinogens that damage DNA or block the histone modification processes, may also induce fragile sites. Alterations in DNA structure induced by miRNA (possibly via R-loop formation) could have similar effects at these sites. Moreover, the remarkable correspondence between sites of reported hypermethylation and fragile sites suggests that the mutational and epimutational base upon which natural selection can act during carcinogenesis is largely confined to these sites. Their tendency to adopt non-B DNA structures provides a compelling case for how they become available for natural selection.

Each of the tenets of the hypothesis is supported by cytogenetic, DNA methylation and enzymological evidence. Enzymological and biological evidence from our laboratory suggests that DNMTs have evolved to recognize non-B DNA structures, like those associated with FRAXA in fragile X-linked mental retardation, and FRA11I/FRA11C in breast and prostate cancer \[[@B20],[@B107],[@B110]\], suggesting that DNMTs play an obligate role in the suppression of non-B DNA structures \[[@B116],[@B117]\] along with associated repair systems. Given an obligate role for DNMTs in the suppression of non-B structure formation, the role of helicases in the process can be better understood. In general, deficiencies in helicases, such as ATRX, HELLS, BLM and WRN, have been shown to result in either global genomic demethylation \[[@B118],[@B119]\], gene activation \[[@B10]\], or both global demethylation and gene activation. Two diametrically opposed interpretations of normal function of these helicases have been proposed. In one interpretation, they are viewed as actively promoting DNA methylation \[[@B118],[@B120]\]. In the alternative interpretation, they are viewed as passively promoting normal DNA methylation by preventing the sequestration of DNMTs \[[@B107],[@B117]\] at unresolved non-B structures \[[@B10]\]. The enzymological evidence supports the alternative interpretation. For example, the WRN helicase has been shown to resolve quadruplex DNA \[[@B15]\] and deficiency appears to result in the accumulation of non-B structures \[[@B10]\]. The evidence suggests that the DNMTs remain bound to non-B DNA sequences containing mispaired cytosines \[[@B107]\], oxidized bases \[[@B121]\] or DNA containing base analogs, such as deoxyuridine (dU) \[[@B122]\], 5azaC-dR or GuaUre-dR \[[@B1]\]. It follows, that in cases of helicase deficiency, DNMT sequestration at a site of hypermethylation will result in global hypomethylation, much like the effects of 5-azacytidine (5azaC-R**)**, 5azaC-dR and GuaUre-dR result in hypomethylation, since tightly bound DNMTs are unable to maintain normal methylation patterns. Moreover, this model (Figure [1](#F1){ref-type="fig"}) and the postulated obligatory role for DNMTs suggests that the cytogenetic overlap between 5azaC-R, 5azaC-dR and GuaUre-dR-induced fragile sites FRA1J and FRA9F, and the undercondensations observed in DNMT3B mutants \[[@B123]\] and knockouts \[[@B124]\], is the result of the complete titration of DNMT3B by non-B structures that remain unresolved and unrepaired after exposure to these compounds. The selective effect on DNMT3B as opposed to DNMT1 can be attributed to its low level of expression relative to DNMT1. Estimates from purification data \[[@B107]\] suggest that DNMT1 levels are in the order of several thousand copies per cell. Northern blotting suggests that the abundance of DNMT3B is ten to twentyfold below that of DNMT1 at a few hundred copies per cell \[[@B125]\]. The DNA footprint of DNMT1 is approximately 23 bp \[[@B126]\]. Thus, a single non-B structure involving even 1,000 bases of single-stranded DNA could sequester approximately 2% of the DNMT1 or 20% of the DNMT3B. Replication stress-inducing agents, such as aphidicolin or distamycin, can be expected to induce multiple non-B regions. During carcinogenesis, multiple rounds of sequential induction of fragile sites by replication stress and carcinogen action could result in global hypomethylation. Moreover, the shattering of metaphase that occurs at high concentrations of 5-aza-CR contrasted with the confined induction of fragile sites at low concentration \[[@B127]\] is consistent with the idea that DNMT3B is knocked out at low concentration and DNMT1 at higher concentration, and that both are obligatorily involved in suppressing fragile sites. Finally, work with the TET dioxygenases \[[@B16]-[@B19]\] and the response of DNMTs to 5-hydroxymethylcytosine (hmC) strongly suggest that hydroxymethylation at repaired and methylated genes in fragile sites will act to restore the unmethylated active state of these genes (Figure [1](#F1){ref-type="fig"}B).
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